Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The study will evaluate the safety and efficacy of Patupilone in adult patients with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Epothilone B; Epothilones

Criteria

Inclusion criteria:

• Patients with a histologically/cytologically confirmed diagnosis of advanced solid tumors refractory to or unsuitable for standard therapy, or for whom no standard therapy exists

• Patients with WHO Performance Status of 0-1 ( Karnofsky Performance Status of 80-100)

• At least one measurable lesion

Exclusion criteria:

• Patients with any peripheral neuropathy

• Patients with unresolved diarrhea

• Patients with severe and/or uncontrolled medical conditions or infections that require systemic therapy

Other protocol-defined inclusion/exclusion criteria may apply